RESUMEN
T cell-engaging bispecific antibodies (TCB) are highly potent therapeutics that can recruit and activate cytotoxic T cells to stimulate an antitumor immune response. However, the development of TCBs against solid tumors has been limited by significant on-target toxicity to normal tissues. Probody therapeutics have been developed as a novel class of recombinant, protease-activated antibody prodrugs that are "masked" to reduce antigen binding in healthy tissues but can become conditionally unmasked by proteases that are preferentially active in the tumor microenvironment (TME). Here, we describe the preclinical efficacy and safety of CI107, a Probody TCB targeting EGFR and CD3. In vitro, the protease-activated, unmasked CI107 effectively bound EGFR and CD3 expressed on the surface of cells and induced T-cell activation, cytokine release, and cytotoxicity toward tumor cells. In contrast, dually masked CI107 displayed a >500-fold reduction in antigen binding and >15,000-fold reduction in cytotoxic activity. In vivo, CI107 potently induced dose-dependent tumor regression of established colon cancer xenografts in mice engrafted with human peripheral blood mononuclear cells. Furthermore, the MTD of CI107 in cynomolgus monkeys was more than 60-fold higher than that of the unmasked TCB, and much lower levels of toxicity were observed in animals receiving CI107. Therefore, by localizing activity to the TME and thus limiting toxicity to normal tissues, this Probody TCB demonstrates the potential to expand clinical opportunities for TCBs as effective anticancer therapies for solid tumor indications. SIGNIFICANCE: A conditionally active EGFR-CD3 T cell-engaging Probody therapeutic expands the safety window of bispecific antibodies while maintaining efficacy in preclinical solid tumor settings.
Asunto(s)
Anticuerpos Biespecíficos , Complejo CD3 , Neoplasias del Colon , Receptores ErbB , Animales , Humanos , Ratones , Anticuerpos Biespecíficos/uso terapéutico , Complejo CD3/antagonistas & inhibidores , Neoplasias del Colon/terapia , Receptores ErbB/antagonistas & inhibidores , Leucocitos Mononucleares/metabolismo , Péptido Hidrolasas/metabolismo , Microambiente Tumoral , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
Phthalates (PAEs) are the class of lipophilic chemicals, which are used as additives in the manufacturing of plastics. It results in presence of PAEs in water and beverages because of their migration capacity. Their presence has attracted considerable attention due to their potential impacts on ecosystem functioning and public health. In addition, an enormous number of research articles have been published between 2000 and 2020, which have been identified and their results have been tabulated displaying PAEs analyzed, matrices, sample preparation, analytical method used, the limit of detection (LOD), and recovery percentages. Numerous sample preparation and analytical methods are found which are suitable for the reliable determination of the PAEs. The analysis of the PAEs is difficult due to their ubiquitous presence and their complexity, therefore suitable precautions, should be taken into account. In this review, we provide an overview of various pre-treatment measures and detection methods for PAEs in several types of water and beverages, mainly focusing on the last 20 years published works have been discussed. Pre-treatment methods mainly include liquid-liquid extraction (LLE), solid-phase extraction (SPE), solid-phase microextraction (SPME), liquid-phase microextraction (LPME), and many more rare techniques. Chromatographic and non-chromatographic techniques coupled with or without diodes, spectrophotometers, and detectors, have been described. The concept of "green analytical chemistry" for PAE determination has also been discussed. Hereby, the limitations and challenges in these applications are also included.
Asunto(s)
Microextracción en Fase Líquida , Agua , Bebidas/análisis , Ecosistema , Microextracción en Fase Líquida/métodos , Extracción en Fase Sólida , Agua/análisisRESUMEN
BACKGROUND: Adoptive transfer of chimeric antigen receptor (CAR)-engineered T cells combined with checkpoint inhibition may prevent T cell exhaustion and improve clinical outcomes. However, the approach is limited by cumulative costs and toxicities. METHODS: To overcome this drawback, we created a CAR-T (RB-340-1) that unites in one product the two modalities: a CRISPR interference-(CRISPRi) circuit prevents programmed cell death protein 1 (PD-1) expression upon antigen-encounter. RB-340-1 is engineered to express an anti-human epidermal growth factor receptor 2 (HER2) CAR single chain variable fragment (scFv), with CD28 and CD3ζ co-stimulatory domains linked to the tobacco etch virus (TEV) protease and a single guide RNA (sgRNA) targeting the PD-1 transcription start site (TSS). A second constructs includes linker for activation of T cells (LAT) fused to nuclease-deactivated spCas9 (dCas9)-Kruppel-associated box (KRAB) via a TEV-cleavable sequence (TCS). Upon antigen encounter, the LAT-dCas9-KRAB (LdCK) complex is cleaved by TEV allowing targeting of dCas9-KRAB to the PD-1 gene TSS. RESULTS: Here, we show that RB-340-1 consistently demonstrated higher production of homeostatic cytokines, enhanced expansion of CAR-T cells in vitro, prolonged in vivo persistence and more efficient suppression of HER2+ FaDu oropharyngeal cancer growth compared to the respective conventional CAR-T cell product. CONCLUSIONS: As the first application of CRISPRi toward a clinically relevant product, RB-340-1 with the conditional, non-gene editing and reversible suppression promotes CAR-T cells resilience to checkpoint inhibition, and their persistence and effectiveness against HER2-expressing cancer xenografts.